Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 11/20 | 0.51 |
| ▸ | AKT1 | P31749 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18148082 | 1.00 | CNKSR1 (0.51) | CNKSR1AKT1MMP2CCR2TP53 | |
| SCHEMBL18148027 | 0.88 | CNKSR1 (0.56) | CNKSR1AKT1MMP2CCR2MAPT | |
| SCHEMBL18148026 | 0.88 | CNKSR1 (0.56) | CNKSR1AKT1MMP2CCR2MAPT | |
| SCHEMBL18160911 | 0.88 | CNKSR1 (0.55) | CNKSR1AKT1CCR2TP53MEN1 | |
| SCHEMBL18148041 | 0.82 | LMNA (0.37) | CNKSR1AKT1MEN1KMT2AHDAC1 | |
| SCHEMBL18148044 | 0.82 | LMNA (0.37) | CNKSR1AKT1MEN1KMT2AHDAC1 | |
| SCHEMBL18147978 | 0.77 | ALDH1A1 (0.42) | CNKSR1AKT1MMP2CCR2TP53 | |
| SCHEMBL18148020 | 0.76 | ALDH1A1 (0.42) | CNKSR1AKT1MMP2TP53MEN1 | |
| SCHEMBL18148224 | 0.74 | MAPT (0.42) | CNKSR1MMP2CCR2GAAMAPT | |
| SCHEMBL18148051 | 0.74 | CNKSR1 (0.44) | CNKSR1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885AKT1 780/4885MMP2 4781/4885 |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885AKT1 780/4885MMP2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.